Continuous dopaminergic stimulation and novel formulations of dopamine agonists. - Wikidata - awgldk - TriplyDB

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

http://www.wikidata.org/entity/Q37874192

about

Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials.Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: a systematic review and meta-analysis.Pramipexole extended-release: a review of its use in patients with Parkinson's disease.Advances in dopamine receptor agonists for the treatment of Parkinson's disease.Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.

P2860

Q35109436-0E3CB58D-7D30-46B7-8094-DBA20E5FB3EB Q35716858-551B13FB-5EDC-49CC-8A51-1C1A8D2CDD2E Q37432045-64925192-9C62-4FDB-AEE9-F51E8B7EE217 Q38112219-98BBC748-F401-4FBB-9890-B118535F7DA6 Q38239051-11707A0D-03B9-458B-AD16-B55C99476F97 Q38266818-3F5A0BBB-BCFF-4AD1-AFD0-C1D21AB3779A Q38937096-67D53A8C-2028-4BB4-B6A2-D37BD3E527DF Q47563667-F1EDAA79-3922-4FAB-B87D-A98B771E0792

P2860

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

http://www.wikidata.org/entity/Q37874192

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

@en

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

@nl

type

label

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

@en

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

@nl

prefLabel

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

@en

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

@nl

P1433

Q37874192-767F13B7-4AC2-4A5B-BB86-8CED3B292C79

P1476

Q37874192-46C5649C-4F34-4C10-9288-FA9301B0F63A

P2860

Q37874192-0172E199-E56A-4DC1-BE7D-F1F6FD8782C7

Q37874192-08A4FAE0-EF0C-4113-B3EF-4E9ECC9EEEA8

Q37874192-0FB08FFA-41D6-4FDC-9853-7673E761B305

Q37874192-12E569AA-1FFE-4AF5-92C1-BEA6A84CB9AB

Q37874192-16468570-5AD4-4F34-A229-1F43C97E2CCB

Q37874192-19F1C994-50A9-4BFF-8569-70C82FDDE77D

Q37874192-1A5A4162-6DAA-417F-92C1-04AE1B674812

Q37874192-1B8EA50B-2138-4E60-B1B5-BC0A48A106E2

Q37874192-1E42BDD9-C4BA-42AF-84B7-C13766045B38

Q37874192-22C87C14-47BE-468A-BF5B-D4D0F310F198

P2888

Q37874192-848593CE-3352-4CA9-97A6-E455B96BB760

P304

Q37874192-F90EB0A6-EB26-49D3-A893-4C3AE673B8CC

P31

Q37874192-7C11952E-7955-41AF-AD46-A930DEBC4ECD

P356

Q37874192-B8401A71-D0FA-4376-8742-2A6BFD914872

P433

Q37874192-7F269196-0888-4EB6-9114-23C6549A0565

P478

Q37874192-FC6CB231-397D-4133-BDA7-FDC79F1D2F34

P50

Q37874192-FB8053ED-FF93-4D19-9339-88CF136B82F6

P577

Q37874192-BFD8969B-7B84-49EC-ACAA-405442C9ED1E

P698

Q37874192-E7F28E58-AC3B-45DF-B779-66956C879E73

P921

Q37874192-6e2785e9-e64b-441c-917d-8f03c095d498

P356

S00415-011-6024-Y

P1433

Journal of Neurology

P1476

Continuous dopaminergic stimulation and novel formulations of dopamine agonists.

@en

P2860

Treatment interventions for Parkinson's disease: an evidence based assessment

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.

Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

Continuous dopamine-receptor stimulation in advanced Parkinson's disease.

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

Emerging therapies in the pharmacological treatment of Parkinson's disease.

Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).

P2888

s00415-011-6024-y

P304

S316-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-011-6024-Y

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

258

http://www.w3.org/2001/XMLSchema#string

P50

Fabrizio Stocchi

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21560062

http://www.w3.org/2001/XMLSchema#string

P921